{
    "clinical_study": {
        "@rank": "33547", 
        "arm_group": [
            {
                "arm_group_label": "Lactulose", 
                "arm_group_type": "Experimental", 
                "description": "Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day)."
            }, 
            {
                "arm_group_label": "Lactulose-paraffin", 
                "arm_group_type": "Experimental", 
                "description": "Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day)."
            }
        ], 
        "brief_summary": {
            "textblock": "Hepatic encephalopathy (HE) is an important complication of liver cirrhosis. Lactulose is a\n      first line treatment for HE, but the adherence to this treatment is relatively low, due to\n      side effects such as diarrhea, distention, etc."
        }, 
        "brief_title": "Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cirrhosis", 
            "Hepatic Encephalopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatic Encephalopathy", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Brain Damage, Chronic", 
                "Delirium", 
                "Encephalitis", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Lactulose is a first line treatment for HE, but the adherence to this treatment is\n      relatively low due to side effects. Lactulose-paraffin recently available in the market can\n      be used for the treatment of HE, and possibly have fewer side effects.\n\n      The aim of this study was to compare the adherence of the treatment of lactulose and\n      lactulose-paraffin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Liver cirrhosis\n\n          -  History of an event of hepatic encephalopathy.\n\n          -  Ambulatory patients\n\n        Exclusion Criteria:\n\n          -  Alcoholism with active ingest of alcohol in the last 6 months\n\n          -  Labour turn-overs\n\n          -  Pregnancy\n\n          -  Personal history of surgery in the last 4 weeks\n\n          -  Spontaneous bacterial Peritonitis\n\n          -  Use of neuropsychiatric drugs\n\n          -  Neuropsychiatric disorders (Schizophrenia, bipolar disorder, major depression,\n             dementia and Attention-deficit hyperactivity disorder)\n\n          -  Thyroid disorders without replacement therapy\n\n          -  Renal failure\n\n          -  Hepatic or renal transplant\n\n          -  Personal history of hepatocellular carcinoma\n\n          -  Placement of transjugular intrahepatic portosystemic shunt\n\n          -  Use of a probiotic in the last 6 month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017119", 
            "org_study_id": "GAS-282-10/11-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Lactulose", 
                "Lactulose-paraffin"
            ], 
            "intervention_name": "Comparison between Lactulose and Lactulose-Paraffin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lactulose"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "detoal@yahoo.com", 
                "last_name": "Aldo Torre Delgadillo, M.D. M.Sc", 
                "phone": "54870900", 
                "phone_ext": "2711"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "zip": "14000"
                }, 
                "name": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran"
            }, 
            "investigator": {
                "last_name": "Aldo Torre Delgadillo, M.D. M.Sc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients: Impact on the Recurrence of Encephalopathy, Tolerance and Adherence to Treatment, Costs, and Quality of Life", 
        "overall_contact": {
            "email": "detoal@yahoo.com", 
            "last_name": "Aldo Torre Delgadillo, M.D. M.Sc", 
            "phone": "54870900", 
            "phone_ext": "2711"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Secretaria de Salud", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Provide evidence of better adherence to treatment with lactulose-paraffin in cirrhotic patients with a history of hepatic encephalopathy, which should be reflected in fewer hospitalizations, lower costs and better quality life.", 
            "measure": "Adherence to treatment", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017119"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
            "investigator_full_name": "ALDO TORRE DELGADILLO", 
            "investigator_title": "Principal Investigator.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}